His primary areas of study are Immunology, Antigen, Antibody, Immune system and Immunotherapy. His study in the fields of Epitope and ELISPOT under the domain of Immunology overlaps with other disciplines such as Mannan and Antibody titer. Geoffrey A. Pietersz interconnects Molecular biology, Antigen presentation and Fusion protein in the investigation of issues within Antigen.
His Antibody study deals with Cytotoxic T cell intersecting with Cellular immunity. His work is dedicated to discovering how Immune system, Cell biology are connected with Mannosylation and other disciplines. His work focuses on many connections between Monoclonal antibody and other disciplines, such as Cancer, that overlap with his field of interest in Rheumatoid arthritis, Receptor, Inflammation, Fc receptor and Drug.
Geoffrey A. Pietersz spends much of his time researching Immunology, Antigen, Antibody, Monoclonal antibody and Molecular biology. His work on Immune system, CD8, Dendritic cell and Immunoconjugate as part of general Immunology research is often related to Mannan, thus linking different fields of science. His Immune system research incorporates themes from Inflammation and Cell biology.
His research integrates issues of Cytotoxic T cell, Antigen presentation, Mannose and Immunotherapy in his study of Antigen. His Monoclonal antibody study integrates concerns from other disciplines, such as Cancer, Cancer research, In vitro and In vivo. His study looks at the relationship between Molecular biology and topics such as Peptide sequence, which overlap with Fc receptor.
His primary areas of investigation include Antigen, Immune system, Cancer research, Immunotherapy and Immunology. His Antigen research is multidisciplinary, relying on both Cytotoxic T cell, Antibody and Pathology. Geoffrey A. Pietersz has researched Antibody in several fields, including Binding protein and Drug.
His Immune system research includes elements of Inflammation, C-reactive protein and Apoptosis. His work investigates the relationship between Immunotherapy and topics such as Dendritic cell that intersect with problems in Cancer immunotherapy, Mannose receptor, Antigen Targeting, Ex vivo and Adenocarcinoma. His study on Immunology is mostly dedicated to connecting different topics, such as In vivo.
His primary scientific interests are in Antigen, Dendritic cell, Immunotherapy, Ex vivo and Antigen Targeting. His Antigen study combines topics from a wide range of disciplines, such as Hematopoietic stem cell transplantation, Chemotherapy, Monomethyl auristatin E, Lymph node and Positron emission tomography. His biological study spans a wide range of topics, including Mucin, Ovarian cancer, Epithelial ovarian cancer and Adenocarcinoma.
His Immunotherapy study frequently draws connections between adjacent fields such as Pathology. His work deals with themes such as Epitope, Cancer and Molecular imaging, which intersect with Pathology. Geoffrey A. Pietersz has included themes like Mannose receptor, Immune system, Immunology and Cancer immunotherapy in his Ex vivo study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors
Theodora Fifis;Anita Gamvrellis;Blessing Crimeen-Irwin;Geoffrey A Pietersz.
Journal of Immunology (2004)
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
P. Mark Hogarth;P. Mark Hogarth;P. Mark Hogarth;Geoffrey A. Pietersz;Geoffrey A. Pietersz;Geoffrey A. Pietersz.
Nature Reviews Drug Discovery (2012)
Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.
V. Karanikas;L.-A. Hwang;J. Pearson;C.-S. Ong.
Journal of Clinical Investigation (1997)
OXIDATIVE/REDUCTIVE CONJUGATION OF MANNAN TO ANTIGEN SELECTS FOR T1 OR T2 IMMUNE RESPONSES
Vasso Apostolopoulos;Geoffrey A. Pietersz;Bruce E. Loveland;Mauro S. Sandrin.
Proceedings of the National Academy of Sciences of the United States of America (1995)
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].
Vasso Apostolopoulos;Geoffrey A Pietersz;Anastasios Tsibanis;Annivas Tsikkinis.
Breast Cancer Research (2006)
Cell-mediated immune responses to MUC1 fusion protein coupled to mannan
Vasso Apostolopoulos;Geoffrey A. Pietersz;Ian F.C. McKenzie.
Antibody conjugates for the treatment of cancer
Geoffrey A. Pietersz;Ian F. C. McKenzie.
Immunological Reviews (1992)
Mannan-MUC1 - Pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma
Bruce E Loveland;Anne Zhao;Shane C White;Hui K Gan.
Clinical Cancer Research (2006)
Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo
Kuo-Ching Sheng;Martha Kalkanidis;Dodie S. Pouniotis;Sandra Esparon.
European Journal of Immunology (2008)
Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells
Kuo-Ching Sheng;Dodie Pouniotis;Mark Dexter Wright;Choon K Tang.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: